leadf
logo-loader
viewKazia Therapeutics Ltd
(
ASX:KZANASDAQ:KZIA
)

Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

Quick facts: Kazia Therapeutics Ltd

Follow
ASX:KZA

Price: 1.58 AUD

Market Cap: $208.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics bolsters pipeline with new first-in-class oncology drug...

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott soon after entering into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European drug discovery and development company....

on 27/4/21

2 min read